Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
In recent years, targeted radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate for neuroendocrine tumours has yielded promising results. This therapy may be further improved by using individualized dosimetry allowing optimization of the absorbed dose to the tumours and the normal organs. The aim of this study was to investigate the feasibility and reliability of individualized dosimetry based on SPECT in comparison to conventional planar imaging.
Attenuation-corrected SPECT data were analysed both by using organ-based volumes of interest (VOIs) to obtain the total radioactivity in the organ, and by using small VOIs to measure the tissue radioactivity concentration. During the first treatment session in 24 patients, imaging was performed 1, 24, 96 and 168 h after [177Lu-DOTA0, Tyr3]octreotate infusion. Absorbed doses in non tumour-affected kidney, liver and spleen were calculated and compared for all three methods (planar imaging, SPECT organ VOIs, SPECT small VOIs).
Planar and SPECT dosimetry were comparable in areas free of tumours, but due to overlap the planar dosimetry highly overestimated the absorbed dose in organs with tumours. Furthermore, SPECT dosimetry based on small VOIs proved to be more reliable than whole-organ dosimetry.
We conclude that SPECT dosimetry based on small VOIs is feasible and more accurate than conventional planar dosimetry, and thus may contribute towards optimising targeted radionuclide therapy.
KeywordsNeuroendocrine tumours Individualized dosimetry Targeted radionuclide therapy [177Lu-DOTA0, Tyr3]Octreotate
The authors would like to express their gratitude to Professor Eric Krenning and Professor Dik Kwekkeboom, for generously sharing their experience and the peptide supply. They also wish to thank the staff at the Divisions of Nuclear Medicine and Endocrine Oncology (78D), Uppsala University Hospital, for their friendly assistance.
- 12.Stabin M. Fundamentals of nuclear medicine dosimetry. Springer. 2008; ISBN 978-0-387-74578-7.Google Scholar
- 17.Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2009;36:e-pub ahead of print.Google Scholar
- 19.Leide-Svegborn S. Radiation exposure of the patient in nuclear medicine. Experimental studies of the biokinetics of 111In-DTPA-D-Phe1-octreotide, 99mTc-MIBI, 14C-triolein and 14C-urea and development of dosimetric models. Dissertation: Lund University, 1999.Google Scholar
- 20.ICRP. ICRP Publication 23. Reference man: anatomical, physiological and metabolic characteristics. Elsevier; 1975.Google Scholar
- 21.Stabin M, Siegel J, Lipsztein J, et al. RADAR (RAdiation Dose Assessment Resource). http://www.doseinfo-radar.com/RADARphan.html. Accessed 14 July 2009.